Syarikat Takaful Malaysia Keluarga Berhad chief distribution officer Yassir Azlin (fourth from left) and general manager Lim Siew Ping (sixth from right) at the Takaful Malaysia Employee Benefits Symposium 2024.
MALAYSIA’S first takaful operator, Syarikat Takaful Malaysia Keluarga Berhad (Takaful Malaysia), recently unveiled the Cancer Precision Medicine Rider.
The new product – launched at the Takaful Malaysia Employee Benefits Symposium 2024 in Kuala Lumpur, is an optional medical rider that corporate clients can enrol for their employees and eligible dependents.
The Cancer Precision Medicine Rider is designed to harness the advantages of precision medicine and targeted therapies, aiming to increase the effectiveness of cancer treatments while minimising side effects.
It offers an additional layer of cancer coverage that complements existing medical plans, providing customers with enhanced protection in addition to their existing medical coverage plan.
In a statement, Takaful Malaysia highlighted that corporate clients can choose from three plans, each offering access to precision medicine and genomic testing. These services enable a more accurate cancer diagnosis by analysing the genetic profile of the illness.
The medical rider includes a cashless facility for targeted therapies and genomic testing at panel hospitals and approved laboratories for molecular testing, as outlined in the medical plan’s terms and conditions.
Furthermore, the Cancer Precision Medicine Rider provides options to include patient assistance and rehabilitation care, supporting patients in their recovery following precision medicine or targeted therapy.
Takaful Malaysia reiterated its commitment to expanding its comprehensive and affordable suite of Islamic insurance solutions to meet the evolving needs of its clientele.
For further information about Takaful Malaysia’s Cancer Precision Medicine Rider for employee benefits, please contact 1-300 88 252 385 or email csu@takaful-malaysia.com.my
